RxDoctor Payments Data

Carl Hoegerl, DO

Neurology · Lynchburg, VANPI 1477635647

Payments from drug & device makers

$2,039in general payments, 2019–2025

Across 60 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$361
  • AstraZeneca$300
  • TG Therapeutics, Inc.$238
  • AbbVie$192
  • Amneal Pharmaceuticals LLC$145
  • CSL Behring$131
  • plus $673 from 14 others

What the payments were for

  • Food & beverage$1,51574%
  • Education$52426%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,039 in reported general payments places this provider in the 50th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$22,400
Medicare patients
131
Services billed
181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab20$173,307
Teriflunomide41$51,615
QuliptaAtogepant13$17,379
ExelonRivastigmine12$8,097
Carbidopa-LevodopaCarbidopa/Levodopa190$3,099
Dimethyl Fumarate12$2,239
Gabapentin205$2,095
Levetiracetam58$1,104
Topiramate106$890
Baclofen42$806
Carbidopa-Levodopa ErCarbidopa/Levodopa23$568
Phenobarbital21$553
Memantine Hcl43$551
Divalproex Sodium ErDivalproex Sodium14$538
Carbamazepine ErCarbamazepine11$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$192$17,37913 claims
NovartisExelon$59$8,09712 claims
Upsher-smith Laboratories LLCTopiramate$18$890106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 474 neurology providers in Virginia.

Other neurology in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →